Development and characterization of ADC999: A novel, potent orally available Wee1 inhibitor with robust antitumor efficacy in vivo

被引：0
|
作者：
Gavory, Gerald
O'Dowd, Colin
Rozycka, Ewelina
Boyd, Caroline
Gorges, Beronia
McLean, Estelle
Daubriac, Julien
Rountree, Shane
Shepherd, Steven
Burton, Stephanie
McFarland, Mary
Treder, Adam
Wilkinson, Andy
Burkamp, Frank
Harrison, Tim
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-LB-319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-319
引用
收藏
页数：2
相关论文
共 50 条
  • [31] NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability
    Montagnoli, Alessia
    Rainoldi, Sonia
    Ciavolella, Antonella
    Ballinari, Dario
    Caprera, Francesco
    Ceriani, Lucio
    Lupi, Rosita
    Ciomei, Marina
    Felder, Eduard
    Isacchi, Antonella
    Donati, Daniele
    Galvani, Arturo
    Papeo, Gianluca
    CANCER RESEARCH, 2016, 76
  • [32] ON 123300, an orally administered novel CDK4/6+ARK5 inhibitor, exhibits potent antitumor activity in vivo: comparative studies with Palbociclib
    Patel, Shraddha
    Pancholi, Priya
    Visal, Tanvi
    Samant, Amruta
    Kansara, Dhvanir
    Rajadhyaksha, V. J.
    Hoffman, Benjamin S.
    Maniar, Manoj
    Sehdev, Vikas
    CANCER RESEARCH, 2017, 77
  • [33] Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody
    Zeng, Shenxin
    Wu, Mingfei
    Jin, Yuyuan
    Ye, Yingqiao
    Xia, Heye
    Chen, Xinyi
    Che, Jinxin
    Wang, Zunyuan
    Wu, Ying
    Dong, Xiaowu
    Chen, Yinqiao
    Huang, Wenhai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 267
  • [34] Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
    Haarberg, H. Eirik
    Paraiso, Kim H. T.
    Wood, Elizabeth
    Rebecca, Vito W.
    Sondak, Vernon K.
    Koomen, John M.
    Smalley, Keiran S. M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) : 901 - 912
  • [35] Preclinical anti-tumor efficacy and mode of action of a novel, orally available, selective MKNK1 inhibitor [BAY 1143269]
    Santag, Susann
    Siegel, Franziska
    Wegner, Antje Margret
    Schneider, Claudia
    Boemer, Ulf
    Eis, Knut
    Puehler, Florian
    Michels, Martin
    von Nussbaum, Franz
    Ziegelbauer, Karl
    Mumberg, Dominik
    Petersen, Kirstin
    CANCER RESEARCH, 2015, 75
  • [36] In vitro characteristics, anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct factor Xa inhibitor, DU-176b.
    Morishima, Y
    Furugohri, T
    Isobe, K
    Honda, Y
    Matsumoto, C
    Shiozaki, Y
    Muramatsu, S
    Sugiyama, N
    Shibano, T
    BLOOD, 2004, 104 (11) : 515A - 515A
  • [37] Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy
    Liu, Chenglong
    Zhou, Feilong
    Yan, Ziqin
    Shen, Lian
    Zhang, Xichen
    He, Fenglian
    Wang, Heng
    Lu, Xiaojie
    Yu, Ker
    Zhao, Yujun
    Zhu, Di
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (13) : 2651 - 2670
  • [38] Development of highly selective, potent, orally available PIM1 inhibitor BLX0631 shows a therapeutics potential in multiple myeloma models
    Li, Zhaoang
    Lin, Chenyu
    Bearss, David J.
    Vankayalapati, Hariprasad
    CANCER RESEARCH, 2024, 84 (06)
  • [39] NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models
    Ardini, Elena
    Banfi, Patrizia
    Avanzi, Nilla
    Ciomei, Marina
    Polucci, Paolo
    Cirla, Alessandra
    D'Anello, Matteo
    Borgia, Andrea Lombardi
    Motto, Ilaria
    Cristiani, Cinzia
    Ballinari, Dario
    Felder, Eduard
    Donati, Daniele
    Galvani, Arturo
    Isacchi, Antonella
    Menichincheri, Maria
    CANCER RESEARCH, 2018, 78 (13)
  • [40] KW-2450, a novel orally-active dual IGF1R/IR inhibitor: Antitumor effects in vitro and in vivo
    Maekawa, Yoshimi
    Koizumi, Fumito
    Kashima, Naomi
    Suzuki, Masayo
    Umehara, Hiroshi
    Takahashi, Hiroko
    Nakamura, Hiroaki
    Nara, Shinji
    Nakazato, Tomoyuki
    Kanda, Yutaka
    Takahashi, Takeshi
    Akinaga, Shiro
    Shiotsu, Yukimasa
    Soga, Shiro
    CANCER RESEARCH, 2011, 71
12345